Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences, Inc., headquartered in Menlo Park, California, is a prominent medical device company dedicated to innovating and commercializing cutting-edge technologies for the treatment of prevalent eye diseases. The company operates through two main segments: Surgical Glaucoma and Dry Eye.
In the Surgical Glaucoma segment, Sight Sciences offers the OMNI Surgical System. This versatile device allows for both canaloplasty and trabeculotomy with a single corneal incision, aimed at reducing intraocular pressure in adults with primary open-angle glaucoma. The efficacy of OMNI has been demonstrated in multiple clinical trials, showing favorable outcomes in lowering intraocular pressure across various stages of glaucoma.
In the Dry Eye segment, the TearCare System is available for ophthalmologists and optometrists. This system helps manage dry eye disease through a single interventional eyelid procedure, providing significant improvements in the signs and symptoms of the condition over time.
Recent clinical trials have highlighted the effectiveness of these devices. For example, the GEMINI Study demonstrated successful results using OMNI combined with cataract surgery, and the SAHARA trial confirmed the benefits of TearCare compared to traditional treatments.
Financially, Sight Sciences derives key revenue from its Surgical Glaucoma segment. The company has seen active customer engagement, as evidenced by the number of OMNI and SION system orders, as well as TearCare SmartLids sales.
For investors and stakeholders, Sight Sciences continues to be a compelling entity with its relentless focus on reimagining eye care through transformative technologies. The company's commitment to improving patient outcomes and expanding its market presence underscores its significance in the ophthalmic medical device industry.
Sight Sciences (Nasdaq: SGHT) has launched the "Don't Wait for Too Late" educational campaign to promote minimally invasive glaucoma surgery (MIGS) as an early intervention for glaucoma. With glaucoma being a leading cause of irreversible blindness, early treatment is crucial. The use of MIGS, particularly the OMNI® Surgical System, offers new opportunities for patients with mild to moderate primary open-angle glaucoma (POAG), emphasizing reduced dependency on eye drops and better intraocular pressure management. The campaign aims to empower optometrists to recommend MIGS effectively.
Sight Sciences (Nasdaq: SGHT) announced preliminary financial results for Q4 and the full year 2021, forecasting total revenue between $14.5 million to $14.8 million for Q4, a 63% year-over-year increase, and full-year revenue between $48.8 million to $49.1 million, up 77%. Surgical Glaucoma revenues for Q4 are projected at $13.8 million to $14.0 million, while Dry Eye revenues are estimated at $0.7 million to $0.8 million. The company also highlighted significant accomplishments, including FDA clearances and advancements in clinical trials, with full results expected in March.
Sight Sciences (Nasdaq: SGHT) has received FDA 510(k) clearance for its TearCare® System to treat meibomian gland dysfunction (MGD), a leading cause of dry eye disease. This clearance allows for localized heat therapy combined with manual gland expression in adult patients with evaporative dry eye. The OLYMPIA study demonstrated significant improvements in tear film stability and symptoms post-treatment. Sight Sciences aims to expand insurance coverage for this treatment to increase patient access, addressing a significant unmet need in the eyecare community.
Sight Sciences (Nasdaq: SGHT) announced participation in the Piper Sandler Annual Virtual Healthcare Conference on November 22, 2021. The company focuses on innovative eyecare technology aimed at transforming care standards. Notable products include the OMNI® Surgical System, a minimally invasive glaucoma surgery device, and the TearCare® System, designed for treating evaporative dry eye disease. A recording of the fireside chat will be accessible on their investor website after the event.
Sight Sciences (Nasdaq: SGHT) announced significant data from the 12-month GEMINI clinical trial showing that the OMNI Surgical System effectively reduces intraocular pressure (IOP) and stabilizes daily IOP fluctuations in patients with open-angle glaucoma. The study included 149 patients, demonstrating that 95% achieved lower peak IOP post-surgery, with a 36% decrease in variability compared to preoperative levels. The results support the device’s potential to improve patient outcomes in glaucoma treatments, encouraging future regulatory developments.
Sight Sciences reported a record revenue of $13.1 million for Q3 2021, marking a 51% increase year-over-year. Gross margins improved to 84% from 70% in the previous year. Surgical glaucoma revenue rose by 58% to $12.4 million, while dry eye revenue declined by 15% to $0.7 million. The company expects total revenue for 2021 to be between $47.5 million and $48.5 million, reflecting an approximate 74% growth from 2020. However, net loss increased to $17.2 million in Q3, compared to $8.1 million a year earlier.
Sight Sciences (Nasdaq: SGHT) has announced FDA approval for its IDE trial aimed at assessing the safety and effectiveness of its new higher volume OMNI device for canal viscodilation in adults with primary open-angle glaucoma (POAG).
The PRECISION clinical trial, a three-armed randomized controlled trial, is set to evaluate the device's efficacy, potentially making it the largest of its kind for minimally invasive glaucoma surgery (MIGS). The study involves 459 patients and compares the higher volume OMNI to the iStent Inject.
Sight Sciences announced it will report its financial results for the quarter ending September 30, 2021, on November 10, 2021. The management will discuss the results in a conference call at 1:30 p.m. PT/4:30 p.m. ET. Investors can access the live and archived webcast through the company’s website or by dialing specified numbers with a passcode. Established in 2011, Sight Sciences focuses on developing products for eye diseases, including the OMNI® Surgical System and TearCare® System.
Sight Sciences (Nasdaq: SGHT) announced promising results from the OLYMPIA trial published in Cornea, aiming to expand the FDA indication for its TearCare® System. This system targets evaporative dry eye disease (DED) caused by meibomian gland dysfunction (MGD), responsible for 86% of DED cases. The trial, enrolling 135 adults, demonstrated non-inferiority of TearCare compared to LipiFlow, showing significant improvements in DED symptoms without serious adverse events. Sight Sciences aims to shift treatment paradigms from drops to device-based interventions.
Sight Sciences has filed a lawsuit against Ivantis, Inc. in the United States District Court for Delaware, alleging infringement of four U.S. patents related to devices and methods for reducing intraocular pressure. The company seeks an injunction to stop the manufacture, use, and sale of Ivantis' Hydrus® Microstent, along with monetary damages for past infringements. CEO Paul Badawi stated this lawsuit aims to protect their market position in canalicular glaucoma surgery. Sight Sciences continues to innovate in glaucoma solutions, enhancing patient care through minimally invasive technologies.
FAQ
What is the current stock price of Sight Sciences (SGHT)?
What is the market cap of Sight Sciences (SGHT)?
What does Sight Sciences, Inc. do?
What products are offered by Sight Sciences in the Surgical Glaucoma segment?
What is the TearCare System?
Where is Sight Sciences, Inc. headquartered?
What were the findings of the GEMINI Study?
How does Sight Sciences contribute to treating dry eye disease?
What financial segment drives Sight Sciences' revenue?
Who can I contact for investor relations at Sight Sciences?
Are there any recent clinical highlights for Sight Sciences?